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ABSTRACT 
Hot-melt extrusion is a viable technology in preparing the pharmaceutical delivery system 
and has been considered as an attractive alternative to conventional processing methods. The 
objective of this study was to utilize the advantage of continuous manufacturing in HME to design 
and evaluate a formulation of topical semisolid ointment. Melt fusion ointments containing 5% of 
acyclovir (ACV) in water-soluble base with PEG 400, PEG 1500, and PEG 3350 polymers at 
various ratio were prepared. A design of experiment using I-optimal design was conducted. This 
design was used to study the influence of polymer ratio on the physicochemical properties of the 
formulations. The desired formulation was selected according to the critical quality attributes 
(CQAs) including stiffness, adhesiveness, and pH. The selected formulation was then prepared 
through HME with an 11 mm modified twin screw configuration and evaluated through texture 
analysis, pH, drug content uniformity, differential scanning calorimetry (DSC), and in vitro drug 
release. The result demonstrated that the selected formulation showed ideal properties required for 
ointments. The pH is suitable for topical administration, DSC profile indicated the API was 
completely dissolved in the base. In vitro drug release profile and drug content uniformity showed 
no significant difference compared with the convention method under the same base ratio. Further, 
ointment prepared by HME has a lower standard deviation in characterization data and has better 
manufacturing efficiency compared with conventionally prepared ointment. In conclusion, hot-
melt extrusion technology has been successfully applied to prepare water-soluble acyclovir 
ointment and could be a promising and time-saving process used to develop semi-solid 
formulations with better quality, consistency and manufacturing efficiency.
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CHAPTER 1: DEVELOPMENT OF CONTINUOUS MANUFACTURING PROCESS OF 
ACYCLOVIR OINTMENT USING HOT-MELT EXTRUSION 
INTRODUCTION 
Hot-melt extrusion (HME) is an established manufacturing process most widely used in 
plastic and food industry. To date, this technology has been recognized by several research groups 
as a viable method to prepare pharmaceutical drug delivery systems[1]. It is a process combining 
mixing, melting raw materials with rotating screws under proper heat and pressure to create 
homogenous mixtures of polymer and API[2]. Currently, HME has been utilized as a promising 
alternative to traditional processing methods. It is an attractive technology and has various 
advantages over other techniques. It is a green technology and does not cause any kind of pollution; 
it is also a solvent-free process hence can be used with a variety of polymers and APIs. Furthermore, 
HME is a continuous manufacturing process which makes it a far more sophisticated technique 
than other pharmaceutical technologies since it is a unit operation and is very easy to scale up. 
Therefore, it is one of the most economical pharmaceutical manufacturing technologies[3]. It can 
be used to make several different formulations like immediate release, sustained release, controlled 
release and targeted oral formulations[4]–[6]. Lately, it is also being used for topical and 
transdermal drug deliveries[7]. It has also been used to produce films and is one of the best 
technologies to be used alongside 3-dimensional printing[8].
Acyclovir (ACV) is a white, crystalline powder in nature with the molecular formula 
C8H11N5O3 (Structure is shown in Figure 1) and a molecular weight of 225. The maximum 
solubility in water at 37℃ is 2.5 mg/mL and has the pKa values of 2.27 and 9.25, indicates the 
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presence of two different ionizable functional groups within its structure. ACV is presented in the 
World Health Organization’s Model List of Essential Medicines as one of the most efficacious, 
safe and cost-effective medicines in a basic health-care system.[9] It is a synthetic purine 
nucleoside analogue and one of the most commonly used antiviral drugs for the treatment of herpes 
simplex virus types 1 (HSV-1), 2 (HSV-2), and varicella-zoster virus (VZV) infections. The 
inhibitory activity of acyclovir is highly selective due to its affinity for the enzyme thymidine 
kinase (TK) encoded by HSV and VZV. This viral enzyme converts acyclovir into acyclovir 
monophosphate, a nucleotide analogue, and is then further converted into diphosphate by cellular 
guanylate kinase and into triphosphate by a number of cellular enzymes [10] Currently, 
commercially marketed brand product is Zovirax 5% Ointment which contains 50 mg of ACV per 
gram in polyethylene glycol(PEG) base. Acyclovir cream has been vigorously used for the 
treatment of cold sores, and it is also used in capsule, tablet, topical and suspension formulations 
for the treatment of various other viral infections with Acyclovir ointments being used as a primary 
treatment for vaginal herpes. Melt fusion method is used for conventional preparation of ointment 
Topical administration has the advantage of higher patient compliance over other routes of 
administration but faces the manufacturing challenges of high time-consumption and inconsistent 
mixing. The polyethylene glycol (PEG) is preferred as an ointment base comprising a mixture of 
a low molecular weight PEG 400 and a higher molecular weight material such as PEG 3350. PEG 
1500 was added to increase the hydrophilicity of the ointment base.  
In the current study, the main objective was to utilize the advantage of the continuous 
process of HME to formulate acyclovir 5% ointment as an achievable process for future industry. 
Force stress degradation studies showed that ACV is stable in alkaline and remained stable under 
the heating temperature of 70℃.[11] Its thermostability makes it a strong candidate for HME. 
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Therefore, the significance of this work is to apply novel technology on preparing the semisolid 
ointment as a potential replacement of the conventional method with potentially similar CQAs as 
compared to the formulation prepared using traditional manufacturing methods.  
Design of Experiment (DoE) is a structured, organized approach to find cause-and-effect 
relationships between controlled input factors of the process and their responses.[12] It represents 
the first choice for rational pharmaceutical development and has been intensively used for the 
implementation of Quality by Design (QbD) in both research and industrial settings. The design 
criteria for the formulation is described as Quality Target Product Profile (QTPP), which provide 
the understanding of the quality, safety, and efficacy and form the basis of Critical Quality 
Attributes (CQAs). There are various designs available today which can be used as a potential 
element to estimate average prediction variance. The best options which could be considered 
focusing on the optimality criteria are G-Optimal designs whose operations are based on 
minimizing maximum prediction variance and I-Optimal designs whose operations are based on 
minimizing average prediction variance. Borkowski and Rodriguez et al. [13]stated that while 
using G-Optimal designs, it is occasionally expected to accept larger prediction variances to 
minimize the maximum variance of prediction and therefore I-Optimal design was suggested over 
G-Optimal design. In this study, mixture design was used to minimize the average prediction 
variance. The mixture design had two different criterions which were under possible consideration, 
D-Optimality criterion and I-optimality criterion. The selection of a better design to minimize the 
average prediction variance was dependent on calculating the I efficiency of the designs. If P1 is 
the average prediction variance of Design 1 and P2 is the average prediction variance of Design 2, 
then the I efficiency of Design 1 would be P2/P1 and I effectiveness of Design 2 would be P1/P2. 
It was found that the I effectiveness of I-Optimal design was larger than D-Optimal design. This 
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is only possible if the average prediction variance of D-Optimal design is larger than that of I-
Optimal design. Because of this reason, Mixture I-Optimal design was used in this study to 
minimize the average prediction variance of the model.[14] 
 
 
Figure 1 Chemical Structure of Acyclovir 
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MATERIALS AND METHODS 
Chemicals 
Acyclovir USP (>99%, Ria International, NJ); Polyethylene glycol 400 (PEG 400, Merck KGaA, 
Germany); Polyethylene glycol 3350 (PEG 3350), Polyethylene glycol 1500 (PEG 1500), 
Propylparaben (Lot No. 2CH0036), Methylparaben (Lot No. 2BK0012) were all purchased from 
Spectrum Chemicals, Gardena, CA; Butylated hydroxytoluene (BHT, Lot No. Q1443, MP 
Biomedicals, LCC, Solon, OH); Sodium phosphate dibasic heptahydrate (MW: 268 g/mol), 
Sodium phosphate monobasic monohydrate (MW: 138 g/mol), Sodium hydroxide pellets (pure, 
Lot: A0340458), Butylated hydroxyanisole (BHA, 96%, Lot: A0336138) were all purchased from 
ACROS Organics; Hydrochloric acid (Certified ACS Plus, Fisher Chemical, Canada). 
 
DoE 
The experimental design was proposed using I-optimal mixture design. This experiment was 
selected based on the minimum average prediction variance. The formulations were differentiated 
by various specified ratios of PEG 400 with PEG 1500 and PEG 3350(1:1). The software used for 
the application of DoE was Design Expert 11. The target profile of the optimized formulation is 
shown in Table 1  
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Table 1 Formulation compositions screening of acyclovir ointments  
Formulation No. PEG 400 PEG 1500 : PEG 3350 (1:1) 
F1 70 30 
F2 65 35 
F3 60 40 
F4 55 45 
F5 50 50 
F6 75 25 
F7 80 20 
*all formulations contain 5% of Acyclovir Ointment, 0.2% of Methylparaben, 0.02% of 
Propylparaben, 0.01% of BHA, 0.02% of BHT 
Table 2 Target profile of Acyclovir Ointment 
Elements Target CQA 
Dosage Form Ointment  
Route of 
Administration 
Topical  
Dosage strength 5.00%  
Dosage design Water-soluble ointment   
Assay 90.0 -110.0 %   
Appearance White, smooth   
Content 
Uniformity 
USP Chapter <3>  
pH 5.5-7.0 Yes 
Adhesiveness Consistent  Yes 
Stiffness Consistent Yes 
In vitro release 
testing 
Rate of release of the drug 
concerning the square root of 
time, R²>0.90 
Yes 
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Preparation of Conventional Ointment 
Water-miscible ointment base composed of PEGs were prepared by the conventional method of 
fusion. A predetermined amount of PEG 400, PEG 3350, and PEG 1500 and other excipients were 
weighed. PEG 400 was mixed with API first in a mortar while PEG 3350 and PEG 1500 were 
warmed first to around 65  5℃ on a hot plate. Combined the two mixtures on the hot plate and 
wait for a minute to uniform the temperature. Stirring the mixture under 65  5℃ until 
homogenized and removed from the hot plate, transferred to a mortar and stirred until congealed. 
Preparation of Hot-Melt Extruded Ointment 
In this study, 11 mm co-rotating twin-screw extruder (Process 11 twin screw extruder, Thermo 
Fisher Scientific) was used.[15] The schematic representation and assembly of the extruder are 
shown in Figure 2 and Figure 3, respectively. Before the manufacturing process, the calibrations 
of the volumetric feeder, portal of the solid phase, and the peristaltic pump, injection of the liquid 
phase are necessary, in order to make sure the solid phase and liquid phase are mixed at an accurate 
ratio. A calibration curve was prepared with the correlation of weight dispensed per minute 
(mg/min) vs. feeder’s set point and weight dispensed per minute vs. RPM (Pump). 5% of ACV 
was mixed with PEG 3350 and PEG 1500 to obtain the physical mixtures (PMs). The PMs were 
added through a volumetric feeder at zone 1, and PEG 400 was introduced in the extruder barrel 
in zone 3, using a peristaltic pump and an injection port after 2 minutes. Extrusion condition was 
under the temperature of 65 ℃ from zone 1 to 5 and 40 ℃ for the rest of the zones. The screw 
configuration was designed with three mixing zone including a mixing zone for PMs, a terminal 
mixing zone to prevent phase separation, and an extended mixing zone at zone 3 where PEG 400 
was injected in to the extruder. The liquid extrudates were collected in one white plastic sealed 
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container and cooled at ambient temperature. The container was stored in dry, dark conditions for 
further characterizations.  
 
Table 3 Finalized formulation 
Feeding Phase Ingredients %wt 
Solid PEG 3350 11.84 
 PEG 1500 11.84 
 ACV 5 
 BHT 0.02 
 BHA 0.01 
 Propyl Paraben 0.02 
 Methyl Paraben 0.2 
Liquid PEG 400 71.06 
 
 
Table 4 Parameters maintained for HME process 
Parameters Description 
Equipment 11 mm co-rotating twin screw extruder 
Screw Design Modified screw 
Barrel Temperature Zone 1-5 (65℃) 
 Zone 6-8, Exit (40℃) 
Pump Feeding Rate 2 RPM  
Torque 0-2% 
Screw Speed 60 RPM 
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Figure 2 Schematic representation of the preparation of ointment by HME 
 
Figure 3 Screw design used for the preparation of ointments 
Differential Scanning Calorimetry (DSC)  
DSC studies were performed to determine the drug-excipient compatibility, melting point, and 
polymorphism or degradation. In this study, pure API, pure base of PEG 3350 and PEG 1500, and 
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drug load ointments formulations by conventional and HME method were physically characterized 
using DSC 25 (TA instruments) along with a Trois software for analyzing the data. DSC 
Approximately 2-5 mg of each sample was weighed and sealed in an aluminum hermetic pan to 
prevent evaporation. The temperature range of the sample was from 25 to 275 ℃ at a heating rate 
of 10 ℃/min under inert nitrogen atmosphere maintaining a flow rate of 50 mL/min 
 
pH measurement 
pH was considered to be a critical quality attribute; therefore, the desired pH of the formulation 
should within the range of 5.5 - 7.0 according to pH of normal human skin. Metteler Toledo InLab 
®Micro pH probe (electrolyte 3 mol/L KCl) was used in this test. Predetermined amount of 
formulation was dissolved in water and pH was measured with the two different concentrations of 
5 % w/v,10% w/v. [15] 
 
Texture Analysis 
Texture Analysis was used to determine the texture properties, stiffness and Adhesiveness to be 
specific in this study. The experiment was conducted on the texture analyzer TA.XT2i (Texture 
Technologies Corp., Scarsdale, NY, USA) with software Texture Exponent 32 (Stable Micro 
Systems) along with a 1-inch diameter probe (TA-3, acrylic cylindrical), and a soft matter kit (TA-
275). The experimental protocol for texture analysis is listed in Table 5 
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Table 5 TA Experimental Protocol 
Settings Parameters Unit 
Sequence Title  3 HOLD UNTIL TIME  
Test Mode Compression  
Pre-Test Speed 0.5 mm/sec 
Test Speed 0.5 mm/sec 
Post-test Speed 5 mm/sec 
Target Mode Distance  
Force 100 g 
Distance 2 mm 
Strain 10 % 
The ointments were applied onto the soft matter and positioned below the texture analyzer’s probe. 
Once the test started, the problem was moving toward the product at pre-text speed till it touched 
the surface of the ointment. The probe produced a deformation of 2 mm of the sample at the test 
speed after reaching the surface and establishing the trigger force. Then, the probe was detached 
from the sample at post-text speed. Before each test, the base of the probe and the surface of the 
soft matter was properly cleaned. Each of the formulations was run in triplicated[16]. 
 
Method of analysis 
ACV content was determined using UV-Visible Spectrometer (Thermo Scientific, Genesys 180) 
equipped with 1 cm matched quartz cuvette under the maximum absorbance wavelength of 254 
nm. Weighted amount of ACV powder equivalent to 100 mg was dissolved 100 mL of 0.1 N 
NaOH. A series of standard solutions containing 1.0-50 µg/mL of ACV were prepared and 
measured under the wavelength against reagent blank.  
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Uniformity of Drug Content 
ACV content in both Conventional method and HME method were estimated by this method. 
Carefully weighted 0.2 g of formulation equivalent to 10 mg off API were taken from different 
regions of the container and mixed with 2 mL Acetonitrile, vortex for 20 seconds and centrifuge 
for 10 minutes with 13,000 rpm at room temperature until the PEG base was completed dissolved. 
Remove the supernatant and add 2mL 0.1 N NaOH as extortion medium to dissolve the drug at a 
concentration of 5 mg/mL. After achieving the complete solubility of the drugs, a 100 µL of 
solution was transferred into 20 mL scintillation vials with 0.1 N NaOH to obtain the concentration 
of 25 µg/mL. The samples were then analyzed by UV-Vis method at maximum wavelength of 254 
nm to determine the drug amount of ACV using the calibration curve above[17], [18]. 
 
In Vitro Release Testing (IVRT) 
The in vitro release testing (IVRT) of conventional and HME ointment equivalent to 50mg of ACV 
was confirmed using modified dissolution apparatus II (immersion cells) and 150 mL capacity 
flask containing freshly prepared Phosphate Buffer (PB, 0.1 N, pH 7.4). SR8-plus dissolution tester 
(Hanson, Chatsworth, US) was maintained at 32 ± 0.5°C and the paddle speed was set at 50 rpm. 
The membrane was selected to be a hydrophobic Tuffryn membrane (0.45 um, 25mm, 1.77 
cm2)[19] and assembled as is shown in the guide[20]. Before starting the dissolution, the 
membrane was pre-wet in the dissolution media for 30 minutes. Ointments were applied onto the 
membrane and sealed inside the cell. The infinite dose of the ointment formulation was applied to 
the membrane. The active diffusion area of the membrane was 1.77 cm2. During the study, 1 mL 
of sample was collected from the flask at time points of 0.5, 1, 2, 3, 4, and 5 hours, respectively. 
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Then, an equal amount of fresh buffer was injected as subsequent. The collected samples were 
suitably diluted and analyzed using UV-Vis system at the wavelength of 254 nm. 
   
Figure 4 a) Assembly diagram, b) immersion cell components, c) SR8-Plus Configuration[20] 
©2012 Hanson Research Corp. 
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RESULTS AND DISCUSSION 
Formulation Screening 
Screening of the formulations was performed based on CQAs with three essential parameters: 
stiffness, adhesiveness, and pH. Texture parameters such as firmness and adhesiveness of semi-
solids are essential for product performance as well as for patient’s compliance. Stiffness relates 
to the viscosity of the product and is denoted by the maximum value of force in the plot of force 
versus time. The adhesiveness relates to spreadability, and it is the area under the negative area 
under the curve.  Suitable formulations were selected based on the CQAs. 
Table 6 Screening of the formulations 
Formulation No. Stiffness (g) Adhesiveness (g.sec) pH 
F1 974.348 397.723 5.63 
F2 1255.828 585.299 5.47 
F3 2046.877 532.354 5.69 
F4 3221.873 331.856 5.82 
F5 3843.933 412.128 6.62 
F6 683.094 367.808 5.58 
F7 437.318 259.561 5.36 
All the formulations had a different ratio of PEG base and significance has been found only in 
stiffness between each ratio, which means there is no significant effect of and pH on the 
formulations. It can be further demonstrated by p-value greater than 0.05. 
 15 
Adhesiveness  
Table 7 ANOVA of the tested formulation for adhesiveness 
Source 
Sum of 
Squares 
df Mean Square 
F-
value 
p-value 
  
Model 0.0002 2 0.0001 2.83 0.1509 
not 
significant 
⁽¹⁾Linear 
Mixture 
0 1 0 0.8712 0.3935 
 
AB 0.0001 1 0.0001 4.78 0.0804 
 
Residual 0.0002 5 0 
   
Lack of Fit 0.0002 4 0 25.91 0.1462 
not 
significant 
Pure Error 1.46E-06 1 1.46E-06 
   
Cor Total 0.0003 7         
 
The Model F-value of 2.83 implies the model is not significant relative to the noise. There is a 
15.09% chance that an F-value this large could occur due to noise. P-values less than 0.0500 
indicate model terms are significant. In this case A, B are significant model terms. Values higher 
than 0.1000 indicate the model terms are not significant. If there are many insignificant model 
terms (not counting those required to support hierarchy), model reduction may improve your 
model. The Lack of Fit F-value of 25.91 implies the Lack of Fit is not significant relative to the 
pure error. There is a 14.62% chance that a "Lack of Fit F-value" this large could occur due to 
noise. Non-significant lack of fit is good -- we want the model to fit. 
Table 8 Fit statistics for the design 
Std. Dev. 0.0055 R² 0.5307 
Mean 0.0512 Adjusted R² 0.343 
C.V. % 10.8 Predicted R² -0.6914 
    Adeq Precision 4.3218 
 
A negative Predicted R² implies that the overall mean may be a better predictor of your response 
than the current model. In some cases, a higher order model may also predict better. Adeq Precision 
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measures the signal to noise ratio. A ratio greater than 4 is desirable. The ratio of 4.322 indicates 
an adequate signal. This model can be used to navigate the design space. 
Table 9 Coefficients in terms of coded factors 
Component 
Coefficient 
Estimate 
df 
Standard 
Error 
95% CI 
Low 
95% CI 
High 
VIF 
A-PEG 400 0.0608 1 0.0048 0.0484 0.0732 1.94 
B-PEG 3350: PEG 
1500 
0.0553 1 0.0045 0.0437 0.0669 2.14 
AB -0.0475 1 0.0217 -0.1033 0.0083 3.38 
 
The coefficient estimate represents the expected change in response per unit change in factor value 
when all remaining factors are held constant. The intercept in an orthogonal design is the overall 
average response of all the runs. The coefficients are adjustments around that average based on the 
factor settings. When the factors are orthogonal the VIFs are 1; VIFs greater than 1 indicate multi-
colinearity, the higher the VIF the more severe the correlation of factors. As a rough rule, VIFs 
less than 10 are tolerable. 
 
Figure 5 Two Component mix plots with varying ratios of PEG base in the formulations 
 17 
 
Figure 6 Predicted versus actual values of adhesiveness for the formulations 
Stiffness 
 
Table 10 ANOVA of the tested formulations for Force 
Source Sum of Squares df 
Mean 
Square 
F-value p-value 
  
Model 0.0009 4 0.0002 858.22 < 0.0001 significant 
⁽¹⁾Linear 
Mixture 
0.0009 1 0.0009 3323.64 < 0.0001 
 
AB 0 1 0 70.56 0.0035  
AB(A-B) 2.71E-07 1 2.71E-07 1.03 0.3854  
AB(A-B)² 4.72E-06 1 4.72E-06 17.91 0.0241  
Residual 7.91E-07 3 2.64E-07    
Lack of Fit 7.74E-07 2 3.87E-07 22.92 0.1461 not significant 
Pure Error 1.69E-08 1 1.69E-08    
Cor Total 0.0009 7         
 
The Model F-value of 858.22 implies the model is significant. There is only a 0.01% chance 
that an F-value this large could occur due to noise. P-values less than 0.0500 indicate model 
terms are significant. In this case, A, B, AB, AB(A-B)² are significant model terms. Values higher 
than 0.1000 indicate the model terms are not significant. The Lack of Fit F-value of 22.92 implies 
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the Lack of Fit is not significant relative to the pure error. There is a 14.61% chance that a "Lack 
of Fit F-value" this large could occur due to noise. Non-significant lack of fit is good -- we want 
the model to fit. 
Table 11 Fit statistics for the design 
Std. Dev. 0.0005 R² 0.9991 
Mean 0.0274 Adjusted R² 0.998 
C.V. % 1.87 Predicted R² 0.9782 
    Adeq Precision 78.2092 
The Predicted R² of 0.9782 is in reasonable agreement with the Adjusted R² of 0.9980; i.e. the 
difference is less than 0.2. Adeq Precision measures the signal to noise ratio. A ratio greater than 
4 is desirable. The ratio of 78.209 indicates an adequate signal. This model can be used to 
navigate the design space. 
Table 12 Coefficients in terms of coded factors 
 
 
The coefficient estimate represents the expected change in response per unit change in factor value 
when all remaining factors are held constant. The intercept in an orthogonal design is the overall 
average response of all the runs. The coefficients are adjustments around that average based on the 
factor settings. When the factors are orthogonal the VIFs are 1; VIFs greater than 1 indicate multi-
colinearity, the higher the VIF the more severe the correlation of factors. As a rough rule, VIFs 
less than 10 are tolerable. 
Component Coefficient Estimate df Standard Error 95% CI Low 95% CI High VIF
A-PEG 400 0.0479 1 0.0005 0.0463 0.0495 2.52
B-PEG 3350: PEG 1500 0.0161 1 0.0005 0.0145 0.0178 3.18
AB -0.0174 1 0.0021 -0.0239 -0.0108 3.55
AB(A-B) -0.0036 1 0.0036 -0.0151 0.0078 1.79
AB(A-B)² -0.03 1 0.0071 -0.0525 -0.0074 2.41
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Figure 7 Two component mix plots with varying ratios of PEG base in the formulations 
 
 Figure 8 Predicted versus actual plot for the values of Force for different formulations 
Figure 8 shows that stiffness of the formulation decreases with an increase in the PEG 400 
concentration. The ratio between low molecular weight and high molecular weight of PEG 
significantly affects the stiffness of the ointment formulation. Hence, the desired stiffness can be 
predicted using this parameter in the software.  
 
PH  
The pH of F2 (5.47) and F7 (5.36) are out of the selected range (5.5-7.0) of design space. The pH 
of all other formulations fall in the range, therefore it can be assumed that it has no significant 
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correlation with different formulation ratio, hence would no longer be considered as a parameter 
for formulation screening. 
 
Optimization and Manufacturing process 
After the ratio screening of conventionally prepared formulations, F6 (75:25) with desirable 
properties was selected to be formulated using both conventional method and HME. They were 
then characterized for pH, texture, drug content uniformity, differential scanning calorimetry 
(DSC), and in vitro drug release. 
 
DSC analysis 
DSC is used as thermal analysis to ensure the API dissolved adequately in the formulations. The 
thermogram shows that API was characterized by two endothermic peaks, indicating its melting 
point at 257 ℃ (Figure 9) and its polymorph anhydrous form V at about 150 ℃ [21]. PEG 3350 
and PEG 1500 are semi-crystalline polymers and were found to melt in the range of 60-70℃ and 
40-50 ℃, respectively. After extrusion, the endotherm peaks of API were not preserved since the 
drug has completely dissolved. There is partial crystallization seen in the formulations which can 
be attributed to PEG since the characteristic peak of PEG has subsided and has shifted to a slightly 
lower temperature. 
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Figure 9 DSC thermogram of Acyclovir, excipients and different ointment formulations 
 
Uniformity of Drug Content 
Uniform mixing of the API with ointment base is one of the challenging tasks in manufacturing of 
topical semi-solids. Uniformity of drug content indicates the efficiency of the mixing process. In 
this study, we found that the drug content in the hot-melt extruded ointment was 94.27 % ± 0.64%, 
and in the conventional ointment was 97.84% ± 0.98%. Both of the formulations are within the 
targeted range between 90 – 110 %, indicated the suitability for ointment base.[22] It is evident 
from the result that modified screw configuration used in the study was effective resulting in a 
product with uniform drug content. 
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Table 13 Formulation properties 
Formulation Drug Content Adhesiveness Stiffness pH 
HME 94.27 % ±0.64% 358.930 ± 5.434 684.840 ± 5.375 5.67 ± 0.07 
Conventional 97.84% ± 0.98% 361.526 ± 19.629  669.328 ± 14.277 5.63 ± 0.14 
 
In vitro Release testing (IVRT) 
The immersion cells apparatus was used to assess the release of acyclovir from both of the 
formulations using Tuffryn membrane in phosphate buffer (0.1N, pH 7.4). The immersion cell 
method is a modified USP Apparatus II, which is the most readily available apparatus used by 
most researchers worldwide. It has been reported the advantage of better consistency compared 
with diffusion cells in earlier research[23], [24]. Besides, the membrane selection is essential in 
IVRT because different physicochemical properties of the commercially available synthetic 
membranes may have different influence on release rate. Tuffryn membrane was selected because 
the lower protein binding property is more preferable for acyclovir as a relatively polar drug[25]. 
The in vitro drug release studies were carried out for 5 hours. Data were linearized using the square 
root of time transformation and linear plots were obtained by plotting the cumulative amounts 
released per square root of time. The coefficient of determination was R2 > 0.95 (P=0.68, P>0.05), 
indicated no significant difference observed between conventionally prepared formulation and 
HME formulation.  
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Figure 10 In vitro drug release profile of conventional and HME formulation 
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CONCLUSION 
In this study, topical ointments of 5% acyclovir were prepared by the HME technology as well as 
the conventional technique and characteristic properties were compared between the formulations. 
It can be confirmed from the DSC profile that model API has completely dissolved in the excipient. 
No degradation was observed in the formulation profile. The CQAs, including texture and in-vitro 
release testing from HME showed similar results with conventional formulations. It was observed 
that on increasing the concentration of solid phase (PEG 3350 and PEG 1500) the stiffness 
increased to a certain point and then the stiffness started decreasing. pH and adhesiveness were 
barely influenced by the composition ratio. Therefore, according to the design, it can be observed 
that stiffness is significantly influenced by the composition of different formulations. Further, it 
was noticeable that formulations prepared by HME have a lower standard deviation in the 
characterization results, indicating the advantage of consistent and reproducible results of HME. 
In conclusion, the HME technology has been successfully applied to prepare semisolid dosage 
form and could be a promising and time-saving process used to develop semi-solid formulations 
with better quality, consistency and manufacturing efficiency.  
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